In the ARANOTE trial, darolutamide combined with ADT significantly delayed disease progression and maintained quality of life for patients with metastatic hormone-sensitive prostate cancer, supporting its use as a chemotherapy-free option.
Pedro Barata, MD, MSc, FACP
Advertisement
Articles by Pedro Barata, MD, MSc, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Therapeutic Cancer Vaccines: Are We There Yet?
2
Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy
3
Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy
4
Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer
5
